Board of Directors

Lee Meisel, MD, JD, MPH
President of Windsor Bay Capital, Inc.

Lee Meisel is president of Windsor Bay Capital, Inc. and managing member of Orion Capital Group, LLC. He currently serves as a director of Targa Therapeutics Corporation.

Dr. Meisel previously was Vice President, Operations and director of CPS Chemical Corporation. While at CPS Chemical, he was a member of the executive management team that sold the company to Allied Colloids in the United Kingdom. At CPS, he was co-inventor of several patented chemical processes that covered numerous patented new compositions of matter. Dr. Meisel has worked as a corporate and securities attorney for the biotechnology industry at Brobeck, Phleger and Harrison in Palo Alto, California and as Chief of the Department of Anesthesia for Kaiser Permanente Medical Center in San Francisco.

He received his law degree from Stanford Law School and completed his medical training as a fellow in critical care medicine and a resident in anesthesiology at Harvard Medical School. His Masters of Public Health degree is from the Harvard School of Public Health.

Paul A. Mieyal, PhD, CFA
Vice President of Wexford Capital LLC

Paul A. Mieyal, PhD, CFA is a Vice President of Wexford Capital LLC, an SEC registered investment advisor with over $5 billion of assets under management located in Greenwich, CT. Prior to that, he was Vice President in charge of healthcare investments for Wechsler & Co., Inc., a private investment firm and registered broker-dealer. Dr. Mieyal serves as a Director of Tigris Pharmaceuticals, Inc., Danube Pharmaceuticals, Inc., and Microbiogen Pty Ltd. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.

Debra A. Peattie, PhD, MBA
Managing Director of Pleiades Advisors

Debra Peattie, PhD, MBA, is Managing Director of Pleiades Advisors, an advisory company that serves early and mid-stage life science companies. Previously, she was Co-Founder and Chief Technology Officer of Valeo Medical, a women’s health diagnostics company, and President of RCT BioVentures NE, a seed fund focused on early stage diagnostic and therapeutic technologies. Prior to that, she was a limited partner at MPM Capital, LP, where she helped raise and manage the firm’s initial $230 million fund, and a founding scientist of Vertex Pharmaceuticals. Recruited from a Harvard faculty position to join Vertex, Dr. Peattie established and directed the company’s molecular biology division for four years before joining the company’s business development group.

Dr. Peattie received her PhD in biochemistry and molecular biology from Harvard University and an MBA from Harvard Business School.

John A. Quelch, DBA, MBA, MS
Senior Associate Dean and Lincoln Filene Professor of Business Administration at Harvard Business School

John A. Quelch, DBA, MBA, MS is Senior Associate Dean and Lincoln Filene Professor of Business Administration at Harvard Business School. Between 1998 and 2001 he was Dean of London Business School. Prior to 1998, he was the Sebastian S. Kresge Professor of Marketing and Co-Chair of the Marketing Area at Harvard Business School. Professor Quelch's research focus is on global marketing and branding in emerging as well as developed markets.

Professor Quelch is a non-executive director of WPP Group plc, Pepsi Bottling Group, Gentiva Health Services and Inverness Medical Innovations Inc. He also serves pro bono as Chairman of the Port Authority of Massachusetts and as Honorary Consul General of Morocco in New England.

Charles Sanders, MD
Former Chairman and CEO of Glaxo, Inc.

Charles Sanders, MD served as Chief Executive Officer of Glaxo Inc., a pharmaceutical company, from 1989 to 1994, and was the Chairman of the Board of Glaxo Inc. from 1992 to 1995. Dr. Sanders is also on the Boards of Directors of Vertex Pharmaceuticals, Biopure Corporation, Cephalon, Inc., Fisher Scientific International, Icagen, Inc., and Genentech where he is presently the lead director.

Clyde T. Turner
Chairman and CEO of Global Trust Ventures, LLC

Clyde T. Turner is Chairman and Chief Executive Officer of Global Trust Ventures, LLC, a private equity fund he co-founded in 2005 and Chairman and Chief Executive Officer of Turner Investment, Ltd., a general purpose investment company he founded in 1998. He has served as President and Chief Financial Officer then Chairman and Chief Executive Officer of Mandalay Bay Group and has served as Executive Vice President and Chief Financial Officer of Mirage Resorts, Inc.

Mr. Turner serves on the Community Board of Directors of St. Rose Hospitals in Las Vegas, Nevada, and sits on its Quality Control Committee. He serves as a member of the Board of Directors of Sierra Pacific Resources . From 1995 through 2005 Mr. Turner served on the Board of Directors CaPCURE, an organization founded to find a cure for prostate cancer.

Fred Volinsky, MD Chairman
Founder and CEO

Fred Volinsky began his career as an Emergency Physician where he spent 8 years on the attending staff of Massachusetts General Hospital (MGH) and Brigham and Women's Hospital in Boston. He was one of the original faculty members of the Harvard Residency in Emergency Medicine and the Harvard Department of Emergency Medicine at MGH.

While at Harvard, Volinsky developed a medical device that he licensed to Moser Medical. Dr. Volinsky continued to follow his entrepreneurial interests and co-founded Exhale Pharmaceuticals, now known as CoTherix (CTRX-Nasdaq). He left MGH in 2000 to become Managing Director of RCT BioVentures, an early stage life science fund where he was an investor in a variety of biotechnology companies including Cylene Pharmaceuticals, Catalyst BioSciences, Kerberos Proximal Solutions, Imagine Pharmaceuticals, and Arizeke Pharmaceuticals. He has held Directorships at Myometrix, Cylene Pharmaceuticals, Imagine Pharmaceuticals, Kerberos Proximal Solutions, and Catalyst Biosciences.

Dr. Volinsky is a Co-Chairman of the Stanford BioBootcamp and the founder and Co-Chairman of the UCSD BioBootcamp. He is a member of the Advisory Board of the UCSD Cancer Center, the Scientific Advisory Board to the Bailard Life Science Fund, and the Clinical Advisory Board of Catalyst Biosciences. Volinsky is also a consultant to Threshold Pharmaceuticals and Diobex. Dr. Volinsky earned his medical degree at Eastern Virginia Medical School. He completed a residency in Emergency Medicine at Madigan Army Medical center and was elected as a Fellow to the American College of Emergency Physicians. Volinsky spent 6 years as a military physician and was an attending physician at Walter Reed Army Center.